New drug combo for stem cell transplant in hard-to-treat AML
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new conditioning regimen (MTBF) before a donor stem cell transplant for people with acute myeloid leukemia (AML) that has come back or not responded to standard treatment. It aims to see if this approach can safely help prepare the body for the transplant and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have acute myeloid leukemia (AML) that has returned or not responded to at least two rounds of chemotherapy.
- You are able to undergo a donor stem cell transplant.
- You do not have serious heart problems, active infections, or other major uncontrolled medical conditions.
- You do not have active hepatitis B or C, HIV, or another cancer.
- You are willing to follow the study plan and give informed consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests a specific chemotherapy plan followed by a reduced-intensity donor stem cell transplant for people with relapsed or treatment-resistant acute myeloid leukemia (AML), certain myelodysplastic syndromes (MDS), or chronic myelomonocytic leukemia (CMML). It may help by using donor stem cells to rebuild the bone marrow after intensive cancer treatment, in people who are not responding well to standard therapies.
This trial tests a strong chemotherapy and radiation combo followed by a donor stem cell transplant for people with aggressive blood cancers (like AML or MDS) that haven't responded to earlier treatments or came back. It aims to help prevent the cancer from returning.
This trial tests a new combination of three chemotherapy drugs (clofarabine, busulfan, and melphalan) given before a stem cell transplant to treat acute myeloid leukemia (AML) in patients who have responded well to initial treatment. The goal is to improve how well the transplant works and how long patients survive.
This trial tests a chemotherapy conditioning regimen called TBF before a haploidentical stem cell transplant (using cells from a partially matched family donor) in adults ages 55–75 with acute myeloid leukemia that has responded well to initial treatment. The goal is to see if this approach helps older patients tolerate transplant and achieve long-term remission.
This trial tests whether a new drug combination (Dec-FB4) works better than an existing one (FB4) as preparation for a stem cell transplant in people with acute myeloid leukemia that is in remission. The goal is to improve outcomes for patients who have a suitable donor.
This trial tests a new drug combination (SHR2554 plus azacitidine) given before a stem cell transplant to treat aggressive leukemia, myelodysplastic syndrome, or lymphoblastic leukemia. The goal is to reduce cancer cells before transplant and improve outcomes.
Hear when a new Relapse Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.